SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026,…

Pharvaris N.V. · PRESS-RELEASE filed Nov 12, 2026 at 10:28 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 12, 2026 at 10:28 ET

Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rate by 83% vs placebo (p<0.0001) across all HAE types, with 45% of patients attack-free over 24 weeks. The drug was generally well tolerated with no treatment-related serious adverse events. This is a late-stage biotech with a $2.4B market cap, and the data supports its potential as an oral prophylactic therapy for HAE.

  • Phase 3 CHAPTER-3 met primary and all secondary efficacy endpoints with statistical significance
  • Deucrictibant XR reduced monthly HAE attack rate by 83% vs placebo across all HAE types (p<0.0001)
  • In HAE Type 1 or 2, attack rate reduced by 87% vs placebo
  • 45% of deucrictibant-treated participants were attack-free over the entire 24-week treatment period

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access